Form 4: Stoke Therapeutics CEO Sells Shares to Cover Tax Obligations

Stoke Therapeutics CEO, Edward M. Kaye, sold 6,786 shares of common stock to cover tax liabilities related to the vesting of restricted stock units.

Summary

• Edward M. Kaye, CEO of Stoke Therapeutics, sold 6,786 shares of common stock on December 9, 2024.
• The sale was mandated by the company to cover tax withholding liabilities associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $12.9912 per share, with individual transactions ranging from $12.99 to $13.13 per share.
• Following the transaction, Mr. Kaye beneficially owns 61,885 shares of Stoke Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for companies to mandate sales to cover tax liabilities upon vesting of restricted stock units.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of executive compensation packages, which often trigger tax liabilities upon vesting.
• The sale price range is within the normal fluctuations of the stock price.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

Stoke Therapeutics, Edward M. Kaye, CEO, stock sale, tax withholding, restricted stock units, insider trading